reports
Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Result...
Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, November 12, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Informatio...
Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference
Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Stifel 2025 Healthcare Conference to be held in New York on November 11-13, 2025. Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 10:00 a.m. ET on Tuesday, November 11, 2025. A live webcast of the event will be available using this weblink . Alternatively, ...
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Pha...
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolledAdditional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median progression-free survival (“PFS”) of 14.6 months in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer (“ABC”) MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasda...
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 ...
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”) Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study treatment due to a treatment-related adverse event (“TRAE”) MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated clinical resu...
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Tr...
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and in 11.5% of patients treated with gedatolisib + fulvestrant (“gedatolisib doublet”)Study treatment discontinuation due to treatment related adverse eve...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
PSEC PROSPECT CAPITAL CORPORATION
NVCR NOVOCURE LTD.
MTDR MATADOR RESOURCES COMPANY
FCN FTI CONSULTING INC.
AROW ARROW FINANCIAL CORP.
MDU MDU RESOURCES GROUP INC
CULP CULP INC.
PBHC PATHFINDER BANCORP INC.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
BSM BLACK STONE MINERALS LP
HAIN THE HAIN CELESTIAL GROUP
SMRT INC.
CELC SMARTSPACE SOFTWARE
MBIN CELCUITY
CCEL MERCHANTS BANCORP
BCDA CRYO-CELL INTERNATIONAL
DX BIOCARDIA
COO DYNEX CAPITAL INC.
AOUT THE COOPER COMPANIES INC.
ALXO AMERICAN OUTDOOR BRANDS
SMMT INC.
NAUT ALX ONCOLOGY HOLDINGS
ENOV SUMMIT THERAPEUTICS INC
MRVL NAUTILUS BIOTECHNOLOGY INC
UAMY ENOVIS CORPORATION
NCDL MARVEL BIOSCIENCES CORP
NEXT U S ANTIMONY CORP
SFD NUVEEN CHURCHILL DIRECT LENDING CORP
AFCG NEXTSOURCE MATERIALS INC.
SI SMITHFIELD FOODS INC.
JSPR AFC GAMMA
INC.
SHOULDER INNOVATIONS INC
AMPLITUDE HEALTHCARE ACQUISITION CORP
Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial ...
Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract reporting clinical data from the Phase 3 VIKTORIA-1 trial has been selected for an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress, being held October 17-21, 2025. The presentation will provide detail...
- Jonathan Moreland
SNPS SYNOPSYS INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
NGL NGL ENERGY PARTNERS LP
MTDR MATADOR RESOURCES COMPANY
FRPT FRESHPET INC
BUSE FIRST BUSEY CORPORATION
ASA ASA
CELC CELCUITY
MBIN MERCHANTS BANCORP
AROC ARCHROCK INC.
CCEL CRYO-CELL INTERNATIONAL
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ALXO ALX ONCOLOGY HOLDINGS
DLHC DALEIGH HOLDINGS CORP
AMR ALPHA METALLURGICAL RESOURCES INC
OPEN OPENDOOR TECHNOLOGIES INC.
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
NEXT NEXT CAPITAL
RYAN RYAN SPECIALTY GROUP HLDGS INC
KMPH KEMPHARM INC
BUKS BUTLER NATIONAL CORP
OBLG OBLONG INC
VANI VIVANI MEDICAL INC
RH RESTORATION HARDWARE HOLDINGS INC
SMRT SMARTRENT INC
NBBK NB BANCORP INC.
NCDL NUVEEN CHURCHILL DIRECT LENDING CORP
BHRB BURKE HERBERT FINANCIAL SERVICES CORP
CAMP CAMP4 THERAPEUTICS CORPORATION
SI SHOULDER INNOVATIONS INC
MSTR MICROSTRATEGY INCORPORATED
- Jonathan Moreland
MTDR MATADOR RESOURCES COMPANY
ASA ASA
PBHC PATHFINDER BANCORP INC.
NEXT NEXTDECADE
CELC CELCUITY
FGBI FIRST GUARANTY BANCSHARES
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
OPEN OPENDOOR TECHNOLOGIES INC.
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
RYAN RYAN SPECIALTY GROUP HLDGS INC
KMPH KEMPHARM INC
NBBK NB BANCORP INC.
BHRB BURKE HERBERT FINANCIAL SERVICES CORP
CAMP CAMP4 THERAPEUTICS CORPORATION
SI SHOULDER INNOVATIONS INC
- Jonathan Moreland
SBH SALLY BEAUTY HOLDINGS INC.
PRGO PERRIGO CO. PLC
NVCR NOVOCURE LTD.
KURA KURA ONCOLOGY INC.
GLP GLOBAL PARTNERS LP
FRPT FRESHPET INC
FLDM FLUIDIGM
FCN FTI CONSULTING INC.
CPRX CATALYST PHARMACEUTICALS
CE CELANESE CORPORATION
CDNA CAREDX INC
ASA ASA
AROW ARROW FINANCIAL CORP.
MDU MDU RESOURCES GROUP INC
ADC AGREE REALTY CORPORATION
CECE CECO ENVIRONMENTAL CORP.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
BHB BAR HARBOR BANKSHARES
MFIN MEDALLION FINANCIAL CORP.
BSM BLACK STONE MINERALS LP
PLSE PULSE BIOSCIENCES
MLP MAUI LAND & PINEAPPLE CO. INC.
CELC CELCUITY
BRT BRT APARTMENTS
CCEL CRYO-CELL INTERNATIONAL
AEYE AUDIOEYE INC
DLHC DALEIGH HOLDINGS CORP
OPCH OPTION CARE HEALTH INC
SMMT SUMMIT THERAPEUTICS INC
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
NAUT NAUTILUS BIOTECHNOLOGY INC
ENOV ENOVIS CORPORATION
PFHC PROFRAC HLDG CORP
MLYS MINERALYS THERAPEUTICS INC
PROP PRAIRIE OPERATING CO.
DMA DESTRA MULTI ALTERNATIVE FUND
CAMP CAMP4 THERAPEUTICS CORPORATION
SFD SMITHFIELD FOODS INC.
AFCG AFC GAMMA
HYMC INC.
NIQ HYCROFT MINING HOLDING CORPORATION
NIQ GLOBAL INTELLIGENCE PLC
- Jonathan Moreland
Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 M...
Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance MINNEAPOLIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (“Celcuity”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into an amendment to its existing senior secured credit facility with an affiliate of Innovatus Capital Partners, LLC (“Innovatus”) and Oxford Finance LLC, and its affiliates (together, “Oxford”). The amendment increases the total term loan facility size to $...
Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type...
Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program MINNEAPOLIS, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the U.S. Food and Drug Administration (“FDA”) agreed to accept its New Drug Application (“NDA”) for gedatolisib in HR+/HER2- advanced breast cancer (“ABC”) for review under the Real-Time Oncology Review (“RTOR”) program, which facilitates earlier...
Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provid...
Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update Reported statistically significant and clinically meaningful improvement in both primary endpoints from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trialHazard ratios and improvements in median progression-free survival (“PFS”) are unprecedented in HR+/HER2- advanced breast cancer (“ABC”)Expect to submit a New Drug Application (“NDA”) for gedatolisib, based on data from the PIK3CA wild-type cohort, to the U.S. Food and Drug Administration (“FDA”) in the fourth quarter of 2025 Enrollment is on...
Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Resul...
Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information...
Celcuity Inc: 1 director
A director at Celcuity Inc sold 109,325 shares at 44.074USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.75...
Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public offering of $175,000,000 aggregate principal amount of its 2.750% convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”), and its underwritten pub...
Celcuity Inc. Announces Concurrent Public Offerings of Convertible Sen...
Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock MINNEAPOLIS, July 28, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced proposed underwritten public offerings of $150,000,000 aggregate principal amount of its convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and $75,000,000 of shares of its common stock (the “Common Stock” and, such offerin...
Celcuity Announces Clinically Meaningful Improvement in Both Progressi...
Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Hazard Ratios and Improvements in Median PFS areUnprecedented in HR+/HER2- Advanced Breast Cancer (“ABC”) Gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) reduced the risk of disease progression or death by 76% vs. fulvestrant (HR=0.24; 95% CI: 0.17–0.35; p
Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort f...
Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1 trial. Webcast and Conference Call Information The Celcuity management team will host a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.